Ziritaxestat

Unassigned

New Medicines

Idiopathic pulmonary fibrosis

Information

New molecular entity
Galapagos
Galapagos

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Feb 21Development of ziritaxestat has been discontinued after an independent monitoring board, reviewing unblinded data concluded that the benefit-risk profile no longer supported continuing the PIII ISABELA trial programme [11].

Category

Autotaxin (ectonucleotide pyrophosphatase/phosphodiesterase 2, NPP2 or ENPP2) inhibitor
Idiopathic Pulmonary Fibrosis (IPF) is the most common interstitial lung disease, with an estimated incidence in the UK of around 7.44 per 100,000 population [2].
Idiopathic pulmonary fibrosis
Oral